In addition, ALK fusion status has been analyzed in plasma cfDNA from NSCLC patients by using capture based NGS with a specificity of 100% [41], indicating that rearrangement detection through cfDNA sequencing is possible. The gene discussed is ALK; the disease is non-small cell lung carcinoma.